[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Paroxysmal Supraventricular Tachycardia- Pipeline Insight, 2019

October 2019 | 60 pages | ID: P10AB03F2FF0EN
DelveInsight

US$ 1,000.00 US$ 1,250.00 -20 %
Offer valid until December 31, 2019!

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 48 Hours

'Paroxysmal Supraventricular Tachycardia- Pipeline Insight, 2019' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Paroxysmal Supraventricular Tachycardia pipeline landscape is provided which includes the disease overview and Paroxysmal Supraventricular Tachycardia treatment guidelines. The assessment part of the report embraces, in depth Paroxysmal Supraventricular Tachycardia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Paroxysmal Supraventricular Tachycardia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Paroxysmal Supraventricular Tachycardia Understanding

Paroxysmal Supraventricular Tachycardia (PSVT) also known as Supraventricular Tachycardia (SVT) is a rapid heart rate (tachycardia, or a heart rate above 100 beats per minute) that is caused by electrical impulses that originate above the heart's ventricles. Many doctors and other health care professional include all of the many tachycardias that involve the atrioventricular node (AV node) under this classification. Supraventricular tachycardia can be found in healthy young children, in adolescents, and in some people with underlying heart disease. The fast heart rate tends to begin and end suddenly and may last from a few minutes to many hours. It is almost always experienced as an uncomfortable awareness of the heartbeat, such as feeling like the heart is pounding or racing (palpitations). Most episodes of SVT are caused by faulty electrical connections in the heart. SVT also can be caused by certain medicines. Examples include very high levels of the heart medicine digoxin or the lung medicine theophylline. The symptoms of PSVT include heart palpitations, a rapid pulse, a feeling of tightness or pain in the chest, anxiety, shortness of breath, sweating, a pounding sensation in the neck and Fainting (syncope) or near fainting.

Paroxysmal Supraventricular Tachycardia Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Paroxysmal Supraventricular Tachycardia targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Paroxysmal Supraventricular Tachycardia pipeline report covers 10+ companies. Some of the key players include Milestone Pharmaceuticals (Etripamil) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Paroxysmal Supraventricular Tachycardia Analytical Perspective by DelveInsight
  • In-depth Paroxysmal Supraventricular Tachycardia Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
  • Paroxysmal Supraventricular Tachycardia Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

SCOPE OF THE REPORT
  • The Paroxysmal Supraventricular Tachycardia report provides an overview of therapeutic pipeline activity for Paroxysmal Supraventricular Tachycardia across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Paroxysmal Supraventricular Tachycardia therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
  • Detailed Paroxysmal Supraventricular Tachycardia Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Paroxysmal Supraventricular Tachycardia
REASONS TO BUY
  • Establish a comprehensive understanding of the current pipeline scenario across Paroxysmal Supraventricular Tachycardia to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Paroxysmal Supraventricular Tachycardia R&D
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Get in detail information of each product with updated information on each project along with key milestones
  • Devise Paroxysmal Supraventricular Tachycardia in licensing and out licensing strategies by identifying prospective partners with progressing projects for Paroxysmal Supraventricular Tachycardia to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
1. REPORT INTRODUCTION

2. PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (SUPRAVENTRICULAR TACHYCARDIA (SVT))

2.1. Paroxysmal Supraventricular Tachycardia Disease Overview
2.2. Paroxysmal Supraventricular Tachycardia History
2.3. Paroxysmal Supraventricular Tachycardia Symptoms
2.4. Paroxysmal Supraventricular Tachycardia Causes
2.5. Paroxysmal Supraventricular Tachycardia Pathophysiology
2.6. Paroxysmal Supraventricular Tachycardia Diagnosis
  2.6.1. Diagnostic Guidelines

3. PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA CURRENT TREATMENT PATTERNS

3.1. Treatment Guidelines

4. PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA- DELVEINSIGHT’S ANALYTICAL PERSPECTIVE

4.1. In-depth Commercial Assessment
  4.1.1. Paroxysmal Supraventricular Tachycardia companies collaborations, Licensing, Acquisition –Deal Value Trends
    4.1.1.1. Assessment Summary
  4.1.2. Paroxysmal Supraventricular Tachycardia Collaboration Deals
    4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
    4.1.2.2. Paroxysmal Supraventricular Tachycardia Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
  4.2.1. Assessment by Phase of Development
  4.2.2. Assessment by Product Type (Mono / Combination)
    4.2.2.1. Assessment by Stage and Product Type
  4.2.3. Assessment by Route of Administration
    4.2.3.1. Assessment by Stage and Route of Administration
  4.2.4. Assessment by Molecule Type
    4.2.4.1. Assessment by Stage and Molecule Type
  4.2.5. Assessment by MOA
    4.2.5.1. Assessment by Stage and MOA

5. PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA PIPELINE THERAPEUTICS

5.1. Late Stage Products (Phase-III)
  5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
  5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
  5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
  5.4.1. Comparative Analysis
5.5. Inactive Products

6. PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA -PRODUCTS ANALYSIS

6.1. Product Profiles
  6.1.1. Etripamil- Milestone Pharmaceuticals
    6.1.1.1. Product Description
      6.1.1.1.1. Product Overview
      6.1.1.1.2. Mechanism of Action
    6.1.1.2. Research and Development
      6.1.1.2.1. Clinical Studies
        6.1.1.2.1.1. Detailed Study Description
        6.1.1.2.1.2. Study Results
        6.1.1.2.1.3. Clinical Trials: Tabular View
    6.1.1.3. Product Development Activities
      6.1.1.3.1. Tabulated Product Summary
        6.1.1.3.1.1. General Description Table

7. RECENT TECHNOLOGIES

8. PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA KEY COMPANIES

8.1. Milestone Pharmaceuticals
8.2. Cordex Pharma
8.3. CV Therapeutics
8.4. Procter & Gamble
8.5. Novartis
8.6. AOP Orphan Pharmaceuticals AG

9. PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA KEY PRODUCTS

9.1. Etripamil
9.2. Adenosine triphosphate injection
9.3. Tecadenoson
9.4. Lappaconitine
9.5. SDZ WAG
9.6. Landiolol

10. DORMANT AND DISCONTINUED PRODUCTS

10.1. Dormant Products
  10.1.1. Reasons for being dormant
10.2. Discontinued Products
  10.2.1. Reasons for the discontinuation

11. PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA- UNMET NEEDS

12. PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA- FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

14.1. Secondary Research
14.2. Expert Panel Validation

LIST OF TABLES

Table 1. Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Paroxysmal Supraventricular Tachycardia Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products

LIST OF FIGURES

Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Paroxysmal Supraventricular Tachycardia companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Paroxysmal Supraventricular Tachycardia Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs

KEY COMPANIES

Milestone Pharmaceuticals
3M Pharmaceuticals
Cordex Pharma
Eisai
CV Therapeutics
Procter & Gamble
Novartis
Pfizer
Ono Pharmaceutical
AOP Orphan Pharmaceuticals AG
Pfizer



More Publications